N-Ethyl-N-propyltryptamine (EPT) is a synthetic psychedelic tryptamine with an asymmetric N-alkyl substitution — one ethyl and one propyl group on the terminal nitrogen. This places it in the structural space between DET (diethyl) and DPT (dipropyl), and the asymmetric substitution pattern distinguishes it from the symmetric dialkyl analogs. EPT has been documented primarily through community experience reports, with minimal formal pharmacological research.
Community reports characterize EPT as a moderately potent tryptamine with a psychedelic profile broadly consistent with the class — visual phenomena, emotional amplification, altered cognition and time perception — but with a character that some users describe as somewhat distinct from the better-known symmetric tryptamines. Reddit reports document experiences with 4-AcO-EPT (the 4-acetoxy prodrug) and 4-HO-EPT, suggesting interest in the EPT series across its hydroxy, acetoxy, and base forms. Duration is approximately 3–5 hours.
EPT represents an interesting structural data point in the tryptamine pharmacology literature, occupying the asymmetric mixed ethyl-propyl substitution space that has received less documentation than the symmetric analogs. Its availability is limited compared to more commonly encountered tryptamines, and formal safety data is essentially absent.
Safety at a Glance
High Risk- Estimated active range: 30–100 mg orally, with significant individual variability
- Conservative starting doses recommended given limited documentation
- Toxicity: Acute Toxicity No formal toxicological data in humans. Safety profile is inferred from class membership (dialkyl tryp...
- Overdose risk: Fatal overdose from EPT alone, at doses within the typical recreational range, is extremely unlik...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
Duration
insufflated
Total: 2 hrs – 4 hrsHow It Feels
The onset of EPT is almost hesitant in its gentleness. Thirty to fifty minutes after ingestion, the first signs appear as a barely perceptible brightening of colors and a soft, pleasant warmth in the body. The transition is so subtle that, for the first half hour of activity, the user may question whether the substance is active at all. A mild tingling in the fingertips, a slight lightening of mood, and a growing sense of relaxed awareness develop slowly — arriving less like a wave and more like the gradual brightening of dawn.
As the experience reaches its full expression over the next hour, the effects remain gentle but become more clearly defined. Colors are modestly enhanced — warm tones glow a little more brightly, cool tones deepen slightly. Surfaces may show the faintest suggestion of breathing or texture enhancement. Closed-eye visuals are minimal: soft washes of color, perhaps a simple geometric form drifting in and out of focus. The mental effects are a quiet mood lift and a gentle expansion of introspective space — thoughts turn inward with ease, memories surface with a soft clarity, and there is a contemplative stillness that invites reflection without demanding it.
The peak, arriving around sixty to ninety minutes and lasting one to two hours, is a mild, accessible plateau. The headspace is clear and serene; cognitive function is essentially unimpaired. There is a quiet pleasure in sensory experience — music sounds slightly richer, touch is marginally more detailed, and the visual world carries a subtle glow — but none of these enhancements are dramatic enough to be disorienting. The body feels comfortable, warm, and relaxed. Social interaction is easy and natural, neither enhanced nor impaired. EPT at common doses is perhaps the gentlest psychedelic experience available from a tryptamine — a whisper where others are a conversation or a shout.
The comedown is a smooth, almost imperceptible return to baseline over one to two hours. The total duration is three to five hours. There is minimal afterglow — perhaps a lingering sense of calm and a slight brightening of mood that fades by the following morning. EPT is a substance of subtlety and restraint, offering a window into psychedelic space that is narrow but clear, and asking very little of the user in return.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(1)
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Cognitive & Perceptual Effects
Visual(2)
Cognitive(2)
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
Pharmacology
Pharmacology
Mechanism of Action
EPT (N-ethyl-N-propyltryptamine) is an unsubstituted tryptamine that, based on its structural class, is expected to act as an agonist at serotonin receptors — particularly the 5-HT2A receptor, which mediates the perceptual and cognitive effects of classical psychedelics. All psychoactive tryptamines characterized to date function as 5-HT2A agonists, and EPT's structural features are consistent with this mechanism .
Receptor Interactions
Beyond 5-HT2A, psychoactive tryptamines as a class interact with multiple serotonin receptor subtypes (5-HT1A, 5-HT2C) and in some cases with the serotonin transporter (SERT). The relative contribution of SERT activity to the subjective pharmacology varies among tryptamines, and Cozzi et al. (2009) demonstrated that SERT interactions may significantly modulate the psychoactive profile of certain members of this class .
Limited Pharmacological Data
No formal receptor binding studies or in vivo behavioral assays have been published specifically for EPT. Its pharmacological profile is inferred entirely from structural analogy with better-characterized tryptamines such as DMT, DET, and DPT. The asymmetric N-ethyl-N-propyl substitution pattern may produce a distinct receptor binding profile, but this remains uncharacterized .
Metabolism
Recent forensic pharmacological work by Bergh et al. (2024) identified key metabolites of EPT formed by indole ring hydroxylation, providing the first metabolic characterization of this compound. This work was motivated by the compound's emergence as a novel psychoactive substance in European drug markets .
References
- Cozzi NV, et al. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes. Eur J Pharmacol. 2009;610(1-3):12-22.
- Shulgin A, Shulgin A. TiHKAL: The Continuation. Transform Press, 1997.
- Bergh MS-S, et al. Metabolite markers for three synthetic tryptamines N-ethyl-N-propyltryptamine, 4-hydroxy-N-ethyl-N-propyltryptamine, and 5-methoxy-N-ethyl-N-propyltryptamine. Drug Test Anal. 2024;16(9):1073-1085.
Detection Methods
Urine Detection
EPT is not targeted by standard immunoassay-based urine drug screens. As a tryptamine, it is metabolized through monoamine oxidase pathways and produces hydroxylated and deaminated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The short duration of action of most base tryptamines results in a relatively brief detection window compared to longer-acting psychoactive substances.
Blood and Serum Detection
Blood detection windows for EPT are short, typically 4 to 12 hours after oral administration. If smoked or insufflated, peak concentrations occur within minutes and clearance is more rapid. LC-MS/MS is required for reliable blood detection at the low concentrations characteristic of tryptamine compounds. The rapid metabolism by MAO-A significantly limits the time window in which blood sampling can capture meaningful concentrations.
Standard Drug Panel Inclusion
EPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, or any other standard panel analyte. Detection requires specific testing at a reference laboratory capable of novel psychoactive substance analysis. Even extended clinical panels rarely include base tryptamines.
Confirmatory Methods
Confirmatory identification of EPT relies on LC-MS/MS or GC-MS with appropriate reference standards. GC-MS analysis of tryptamines may require derivatization for optimal sensitivity and chromatographic performance. Reference laboratories specializing in novel psychoactive substances provide the most comprehensive detection capabilities. Standard clinical toxicology laboratories generally do not maintain validated methods for base tryptamines.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with EPT, confirming the presence of an indole ring system. This is the primary field identification tool and should be used as the first screening test. The Hofmann reagent provides a confirmatory blue to purple reaction. The Marquis reagent typically shows no reaction or a slight brown-yellow discoloration with base tryptamines. A positive Ehrlich result confirms the tryptamine class but does not identify the specific compound. Multiple reagents should be used together for greater confidence in identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Aminoindane | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FEA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2,5-DMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1B-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-AL-LAD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-MiPLA | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
History
EPT (N-ethyl-N-propyltryptamine) was first documented by Alexander and Ann Shulgin in their 1997 book TiHKAL: The Continuation, which systematically cataloged the synthesis, pharmacology, and subjective effects of tryptamine compounds. The Shulgins synthesized EPT via the standard amide route — condensation of indoleglyoxyl chloride with ethylpropylamine, followed by reduction with lithium aluminum hydride (LAH) .
Despite being synthesized and tested, EPT remained largely obscure for over a decade. It re-emerged in the 2010s as a novel psychoactive substance detected in European drug seizures, prompting forensic and analytical characterization by regulatory laboratories. By 2024, Bergh et al. had published metabolic profiles for EPT to aid forensic identification in biological samples .
References
- Shulgin A, Shulgin A. TiHKAL: The Continuation. Transform Press, 1997.
- Bergh MS-S, et al. Metabolite markers for three synthetic tryptamines. Drug Test Anal. 2024;16(9):1073-1085.
Harm Reduction
Dosing
- Estimated active range: 30–100 mg orally, with significant individual variability
- Conservative starting doses recommended given limited documentation
- Milligram-accurate scale required
Standard Psychedelic Harm Reduction
Test with Ehrlich reagent. Prepare set and setting. Have sober companion available. Avoid dangerous combinations. Benzodiazepines as rescue medication if needed.
Toxicity & Safety
Acute Toxicity
No formal toxicological data in humans. Safety profile is inferred from class membership (dialkyl tryptamines with documented low acute toxicity) and community experience.
Physiological Effects
Standard tryptamine sympathomimetic effects. The larger N-alkyl chains relative to DMT may contribute to body load.
Psychological Risks
Standard psychedelic tryptamine risks apply. Psychosis contraindication, MAOI interaction risk, and HPPD possibility are all applicable.
Addiction Potential
does not produce dependence and has low abuse potential
Overdose Information
Fatal overdose from EPT alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
Due to its relative obscurity, the possession and sale of EPT is unscheduled in most countries.
Germany: EPT is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: EPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United Kingdom: EPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.
United States: EPT is unscheduled in the United States. It may be considered an analogue of DMT, which is a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
Italy: EPT is a Schedule 1 controlled substance.
Responsible use
Research chemical
Psychedelic
Tryptamine
4-AcO-EPT
Ethylpropyltryptamine (Wikipedia)
EPT (Isomer Design)
Discussion
The Small & Handy EPT Thread (Bluelight)
Experience Reports (1)
Tips (8)
Integration is just as important as the experience itself. After using EPT, take time to journal, reflect, or discuss the experience. Insights from psychedelic states can be powerful but need conscious effort to apply to daily life.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of EPT for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid EPT and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
EPT compounds have very little human usage data. Interactions with medications, especially MAOIs, SSRIs, and St. John's Wort, are unpredictable. Clear all supplements and medications before experimenting with these novel tryptamines.
4-AcO-EPT at 30mg can be surprisingly potent despite what some trip reports suggest. Individual sensitivity varies enormously with novel tryptamines. Start with 15-20mg for a first experience and work up from there.
EPT and its 4-substituted variants (4-AcO-EPT, 4-HO-EPT) are described as having a self-contained, somewhat narcotic quality compared to other tryptamines. Users report a meditative, sedating character that is distinct from the more energetic profiles of DMT or MET analogues.
Community Discussions (5)
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- EPT - TripSit Factsheet
TripSit factsheet for EPT
tripsit - EPT - Wikipedia
Wikipedia article on EPT
wikipedia